News

Sai Life Sciences has allotted 92,000 equity shares under ESOP on 14 May 2026. With this allotment, the paid up equity share capital has increased to 21,21,15,515 equity shares of Re 1 each.

Net profit of Sai Life Sciences rose 18.09% to Rs 104.24 crore in the quarter ended March 2026 as against Rs 88.27 crore during the previous quarter ended March 2025. Sales rose 3.91% to Rs 602.14 crore in the quarter ended March 2026 as against Rs 579.51 crore during the previous quarter ended March 2025.For the full year,net profit rose 105.08% to Rs 348.91 crore in the year ended March 2026 as against Rs 170.13 crore during the previous year ended March 2025. Sales rose 29.38% to Rs 2192.49 crore in the year ended March 2026 as against Rs 1694.57 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales602.14579.51 4 2192.491694.57 29 OPM %29.3227.19 -28.7923.94 - PBDT184.25156.29 18 641.05366.28 75 PBT138.94118.80 17 474.19227.70 108 NP104.2488.27 18 348.91170.13 105 Powered by Capital Market - Live News

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Sai Life Sciences has allotted 11,100 equity shares under ESOP on 24 March 2026. With this allotment, the paid up equity share capital has increased to 21,17,79,234 equity shares of Re 1 each. Powered by Capital Market - Live News

Sai Life Sciences has allotted 129,007 equity shares under ESOP on 22 February 2026. With this allotment, the paid up equity share capital has increased to 21,17,58,134 equity shares of Re 1 each. Powered by Capital Market - Live News